Decoy Therapeutics

Q2 FY2026 EarningsQ2 FY26 results beat consensus on bottom-line metrics despite ongoing clinical stage losses. GAAP net loss was $2.37M vs. $2.70M expected, and GAAP EPS was -$4.46 compared to the -$2.88 expected, primarily impacted by a lower-than-projected share count prior to full warrant dilution. Operating loss of $2.63M was better than the $2.80M consensus, driven by disciplined R&D spending on the IMP3ACT platform. Management warned of substantial doubt regarding the company's ability to continue as a going concern, with current cash sufficient only into late 2026.